RE:RE:3 1/2 months in to 2022Hmmm, such a low intellect sensitive little biaatch.
Inmo there will be no share price increase until the company is sold, or worst case trial completion.
This is designed to be valued as a pre clinical micro cap spec stock until it isn't. It always has been. EDT has a preferred buyer valuation that all other P3 companies don't get to enjoy.
where else can you buy millions upon millions of shares of a late stage multi program FDA P3 for 3 dimes or less...for decades!
Think of how long timers fell. They could have left 20 years ago and buy in all they can handle today, tomorrow and the next several months for much much less.